The mechanisms by which
imipramine and
dihydroergosine stimulate the
5-HT syndrome in rats and inhibit the head-twitch response in rats and mice were studied.
Imipramine- and
dihydroergosine-induced stimulation of the
5-HT syndrome was inhibited stereoselectively by
propranolol, a high affinity
ligand for
5-HT1 receptor sites, but not by
ritanserin, a specific 5-HT2 receptor antagonist. (-)-
Propranolol potentiated the inhibitory effect of
imipramine, but not of
dihydroergosine on the head-twitch response, while
ritanserin was without effect. Neither
imipramine nor
dihydroergosine were able to stimulate the
5-HT syndrome in the animals pretreated with
p-chlorophenylalanine. As expected,
8-OH-DPAT, a selective
5-HT1A receptor agonist, stimulated, and 5-HT1B agonists
CGS 12066B and 1-(trifluoromethylphenyl)piperazine (
TFMPP) failed to stimulate the
5-HT syndrome induced in rats by
pargyline and
5-HTP administration. A higher dose of
ritanserin inhibited the syndrome. While
8-OH-DPAT alone produced all behavioral components of the
5-HT syndrome,
dihydroergosine or
imipramine alone even at very high doses never produced
tremor or a more intensive forepaw padding as seen when these drugs were given in combination with
pargyline and
5-HTP. A single administration of (-)-
propranolol also inhibited the head-twitch response. This effect lasted in mice longer than after
ritanserin administration. In in vitro experiments
dihydroergosine expressed approximately twenty-fold higher affinity for 3H-ketanserin binding sites than
imipramine. The results suggest that
imipramine and
dihydroergosine possess two components--one stimulating the
5-HT syndrome in rats by a presynaptic, presumably 5-HT1A-mediated mechanism, and the other inhibiting 5-HT2 binding sites.